Selbyville, Delaware, March 20, 2023 (GLOBE NEWSWIRE) --
The lung cancer market value estimated to reach USD 86.5 billion by 2032, as per a new research report announced by Global Market Insights Inc.
Growing inclination towards minimally invasive procedures for lung cancer treatment owing to their several benefits, coupled with notable advancements in the healthcare industry, is foreseen to significantly boost the market outlook. The demand for robotic-assisted lung resection and video-assisted thoracoscopic surgery (VATS) for lung cancer treatment is rising as these involve quicker recovery, shorter hospital stays, and minimal complications, which is also likely to positively influence the industry scenario.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/5417
Growing adoption of immunotherapy to boost therapy segment expansion
Lung cancer market share from the therapy segment is set to witness significant growth at more than 12% by 2032. The rapid adoption of immunotherapy and numerous innovations such as targeted and hormonal therapy, as well as a combination of chemotherapy and immunotherapy treatments for cancer treatment owing to their effectiveness, convenience, and minimal side effects, are a few factors driving the segment progression.
Browse key industry insights spread across 237 pages with 379 market data tables & 11 figures & charts from the report, “Lung Cancer Market Statistics By Diagnostics & Therapy (Diagnostics {Bronchoscopy, TTNA, Imaging, Tumor Biomarker Test, In Situ Hybridization}, Therapy {Non-invasive [Immunotherapy, Targeted Therapy], Minimally Invasive [Radiofrequency Ablation, Microwave Ablation, Thermal/Cryoablation]}), Indication, (Non-small cell lung cancer, Small cell lung cancer), End-use (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Academia, Specialty Clinics), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2023 – 2032” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/lung-cancer-market
Huge investments for drug expansion to favor the non-small cell lung cancer segment
Non-small cell lung cancer market accounted for over USD 24.5 billion in revenue in 2022. While some revolutionary medications are still in the development stage, key industry players are investing heavily in R&D projects. Additionally, the increasing number of approvals from regulatory authorities for various treatment options is projected to spur segment progress through 2032.
Favorable reimbursement policies for treatment procedures to fuel hospitals segment
Hospitals segment’s growth is attributed to the rising frequency of cancer diagnoses undertaken at hospital due to the availability of technologically advanced biopsies and other instruments used in cancer diagnosis, coupled with favorable reimbursement policies for cancer treatment.
Mounting cancer burden to enhance Asia Pacific revenue
Asia Pacific lung cancer market was valued at over USD 5.5 billion in 2022. Asia is home to 60% of the world's population and bears half of the worldwide cancer burden. The WHO South-East Asia Region reported 1.4 million cancer-related deaths in 2020, with lung cancer accounting for 10.6% of those fatalities. Due to the changes in lifestyle and socioeconomic conditions and the growing population, along with the expanding aging population, which is resulting in mounting cancer cases, are likely to fuel regional business development.
Secure a copy of the premium research report @ https://www.gminsights.com/securecheckout/paymenta/5417?gmpaycod=sugmp
Advancements in treatment of metastatic cancer to define the industry
Major enterprises operating in the lung cancer market are Sanofi, F. Hoffmann-La Roche, Qiagen, Pfizer, Thermo Fischer Scientific, Janssen Pharmaceuticals, Inc., and Quest Diagnostics, among others.
Browse Our Reports Store - GMIPulse @ https://www.gminsights.com/gmipulse
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
